Impel seeks loan leniency to avoid asset sale or bankruptcy

Impel Pharmaceuticals’ money miseries have left it looking to lenders for leniency. In breach of a credit agreement, the developer of intranasal drugs has warned it may have to sell assets or file for bankruptcy if it is unable to restructure its deal and secure fresh funding.